In determining that the illnesses came about from exposure to glyphosate in Roundup, a California jury delivers the biggest loss so far to the herbicide manufacturer in lawsuits about the product.

An early-stage clinical study finds that none of the 25 patients treated developed neurotoxicity or cytokine release syndrome, common hazards of the cancer immunotherapy.

Sequencing of a single gene can spot patients with a dangerous form of mycosis fungoides better than other prognostic tests.  

The therapy, produced by Kite Pharma and owned by Gilead Sciences, is approved for use against some types of large B-cell lymphomas.